Pliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by Needham & Company LLC

Pliant Therapeutics (NASDAQ:PLRX)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $38.00 price objective on the stock. Needham & Company LLC’s price objective points to a potential upside of 183.37% from the stock’s current price.

A number of other analysts have also commented on the company. HC Wainwright reissued a “buy” rating and set a $48.00 price objective on shares of Pliant Therapeutics in a report on Wednesday, February 28th. Royal Bank of Canada increased their price target on Pliant Therapeutics from $50.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, March 5th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $45.67.

Pliant Therapeutics Stock Down 2.8 %

Shares of NASDAQ PLRX opened at $13.41 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.72 and a quick ratio of 17.72. The company has a 50-day moving average price of $14.25 and a 200-day moving average price of $15.41. The stock has a market capitalization of $808.89 million, a P/E ratio of -4.81 and a beta of 1.19. Pliant Therapeutics has a 1 year low of $11.21 and a 1 year high of $24.74.

Institutional Investors Weigh In On Pliant Therapeutics

Several large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its position in Pliant Therapeutics by 97.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,529 shares of the company’s stock worth $27,000 after acquiring an additional 754 shares during the period. Quest Partners LLC bought a new stake in shares of Pliant Therapeutics in the 4th quarter worth approximately $37,000. SG Americas Securities LLC bought a new stake in shares of Pliant Therapeutics in the 1st quarter worth approximately $107,000. Corton Capital Inc. purchased a new position in Pliant Therapeutics in the third quarter valued at approximately $197,000. Finally, Rathbones Group PLC bought a new position in Pliant Therapeutics during the third quarter valued at $203,000. 97.30% of the stock is owned by hedge funds and other institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.